In this week’s edition of InnovationRx, we look at the biotech deal frenzy, Recursion’s incoming CEO, the infant formula ...

AI-based drug developer Recursion’s stock barely moved Wednesday, then dropped Thursday and Friday, after reporting mixed third quarter results, setting the stage for future pipeline announcements—and ...

Dr. James McCaffrey presents a complete end-to-end demonstration of decision tree regression from scratch using the C# language. The goal of decision tree regression is to predict a single numeric ...

Dr. Najat Khan of Recursion shared insights into the creation of the Microglia Map and what it could mean for future drug ...

In a re-evaluation of Hockett's foundational features that have long dominated linguistic theory—concepts like "arbitrariness ...

If the company is forced to offload even 100,000 of its 649,870 coins to meet obligations, it could trigger a systemic ...

Cognitive scientist Steven Pinker’s new work helps understand markets, revolutions, social media and more ...

The latest Call of Duty fumbles its much-anticipated campaign, while zombies and multiplayer modes retain the status quo.

The significance is structural: IBM is not eliminating “underperforming units” but dismantling entire human layers in favor ...

Yet too many CEOs still believe they can solve the problem by outbidding competitors for scarce talent. They can’t. The AI skills gap isn’t a hiring problem. It’s a systems problem.

At ELRIG’s 2025 meeting in GSK’s Stevenage campus, Recursion’s Executive Director of Computational Biology, Dr. Kelly ...